These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

47 related articles for article (PubMed ID: 3882117)

  • 21. Studies of glomerular permeability factor (GPF) in focal segmental glomerular sclerosis and the relationship between GPF and vascular permeability factor (VPF).
    Kondo S; Yoshizawa N; Kusumi Y; Takeuchi A; Torikata C
    Clin Nephrol; 1999 Nov; 52(5):278-84. PubMed ID: 10584990
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Oxygen-dependent injury by a human plasma factor associated with minimal change disease.
    Cheung PK; Baller JF; Bakker WW
    Pediatr Nephrol; 1998 Aug; 12(6):452-8. PubMed ID: 9745867
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Partial purification and characterization of a vascular permeability factor secreted by a human colon adenocarcinoma cell line.
    Lobb RR; Key ME; Alderman EM; Fett JW
    Int J Cancer; 1985 Oct; 36(4):473-8. PubMed ID: 4044056
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A vascular permeability factor in lymphocyte culture supernants from patients with nephrotic syndrome. II. Pharmacological and physicochemical properties.
    Lagrue G; Branellec A; Blanc C; Xheneumont S; Beaudoux F; Sobel A; Weil B
    Biomedicine; 1975 Feb; 23(2):73-5. PubMed ID: 168931
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Corticosteroid-sensitive peripheral blood cells are able to affect glomerular polyanion (GPA) in vitro.
    Bakker WW; Vos JT; Hoedemaeker PJ
    Immunol Lett; 1982 Jul; 5(1):11-4. PubMed ID: 7118183
    [No Abstract]   [Full Text] [Related]  

  • 26. Is 100KF an isoform of hemopexin? Immunochemical characterization of the vasoactive plasma factor 100KF.
    Cheung PK; Stulp B; Immenschuh S; Borghuis T; Baller JF; Bakker WW
    J Am Soc Nephrol; 1999 Aug; 10(8):1700-8. PubMed ID: 10446937
    [TBL] [Abstract][Full Text] [Related]  

  • 27. An alternative view of the proposed alternative activities of hemopexin.
    Mauk MR; Smith A; Mauk AG
    Protein Sci; 2011 May; 20(5):791-805. PubMed ID: 21404362
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Do circulating factors play a role in the pathogenesis of minimal change nephrotic syndrome?
    Bakker WW; van Luijk WH
    Pediatr Nephrol; 1989 Jul; 3(3):341-9. PubMed ID: 2702117
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The glomerular polyanion (GPA) of the rat kidney. III. Further characterization of a vaso-active serum factor which reduces GPA.
    Bakker WW; Roskam G; Hardonk MJ; Vos JT; Bleumink E
    Br J Exp Pathol; 1985 Feb; 66(1):47-55. PubMed ID: 3882117
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The glomerular polyanion (GPA) of the rat kidney II. GPA loss in vitro by a vasoactive serum fraction.
    Bakker WW; Vos JT; Scholma J; Hoedemaeker PJ
    Br J Exp Pathol; 1982 Oct; 63(5):531-8. PubMed ID: 7171477
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Isolation of anionic sialoproteins from the rat glomerulus.
    Nevins TE; Michael AF
    Kidney Int; 1981 Apr; 19(4):553-63. PubMed ID: 7241889
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The glomerular polyanion (GPA) of the rat kidney. I. Concanavalin-A activated cells affect the glomerular polyanion in vitro.
    Bakker WW; van der Laan SM; Vos JT; Hoedemaeker PJ
    Nephron; 1982; 31(1):68-74. PubMed ID: 6213877
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Study on immunopathogenesis of minimal change nephropathy. Effects of mitogens activated lymphocytes on glomerular polyanions in vitro.
    Cheng XJ; Wang YQ
    Chin Med J (Engl); 1989 Jul; 102(7):524-8. PubMed ID: 2517068
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Activation of rabbit Hageman factor by homogenates of cultured rabbit endothelial cells.
    Wiggins RC; Loskutoff DJ; Cochrane CG; Griffin JH; Edgington TS
    J Clin Invest; 1980 Jan; 65(1):197-206. PubMed ID: 6444222
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Contribution of plasma protease inhibitors to the inactivation of kallikrein in plasma.
    Schapira M; Scott CF; Colman RW
    J Clin Invest; 1982 Feb; 69(2):462-8. PubMed ID: 6173399
    [TBL] [Abstract][Full Text] [Related]  

  • 36.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 37.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 38.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 39.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.